, 5.6a-i, 6.6a-i, 7.6a-i, 8.6a-i, 9.6a-i, 10.6a-i, 11.6a-i, 12.6a-i, 13.6a-i, 15.4a and b, 15.5a and b and 15.4-15.15. All of these tables may be found online at http://www.ustransplant.org. decline, reaching 13% for those who received a kidney in 2003, 48% of which cases were treated with antibodies.

No abstract

93 days (range 15-674) post HSCT. Fourteen (40%) were determined to have invasive ADV disease (7 on tissue biopsy). ADV viral load evaluation over time revealed the following: HVL at presentation in 18 (51.4%) (median 1.1x10 4 ,range 7.4x10 5-6.8x10 9 copies/ ml); 10 (28%) progressed to HVL (median 2 log increase from presentation) at a median of 15 days (range 3-56); and LVL-only at any time point in 7 (20%) pts (median 4000 copies/ml, range 600-8866). Fifteen pts with HVL were treated with cidovofir intravenously or/ and CMX001 a median 7 doses (range 1-38). Despite treatment with antiviral therapy 12 pts (92%) with HVL and 7 pts (87.5%) with LVL-HVL died. Mortality was attributable to ADV in 11 (31.4%) pts. All cause 180 day mortality was 74.3% for pts with ADV. Conclusions: ADV viremia was relatively low (8.7%) in this high risk population and similar to the 5% reported in populations receiving conventional transplants. Determination of viral status in patients with clinical symptoms resulted in a relatively high yield of positivity-40%. The mortality attributable to ADV of 30% suggests the need for development of better treatment modalities. The 180 day all cause mortality of 74% suggests ADV viremia complicates other medical conditions and complications of transplant.

Conclusion: Robust planned IMPT for lung cancer, with optional weekly plan adaptation, resulted in adequate target coverage similar to that of PTV-planned VMAT. Inter-fractional variation for breathing and anatomy were considered in this analysis under various error scenarios. With IMPT, no spinal cord dose thresholds were violated and significant and clinically relevant dose reductions were obtained for the heart and lungs compared to VMAT.